Abstract
The SARS-CoV-2 pandemic is limiting both the private and public lives of many people around the world. It is now considered certain that SARS-CoV-2 is transmitted via droplets, smear infection, and aerosol particles. While simple masks, spacing, and hand hygiene significantly reduce the risk of infection via the first two routes mentioned, the risk from aerosol particles remains. These small particles move with the air in the room and spread unhindered throughout it. To reduce the risk of infection from viruses present in aerosol particles, the following options exist. First, good respiratory masks can be worn to reduce the viral load in the inhaled air. Another option is to make the viruses harmless (e.g., by UV light). A third option is to reduce the viral load in the room by bringing in virus-free air and moving contaminated air out or cleaning the air in the room. To investigate how well virus load reduction via ventilation works in a real lecture room, measurements were carried out at the Universität der Bundeswehr München (University of the Federal Armed Forces Munich). The lecture room holds a maximum of approx. 90 people and has a ventilation system as well as 2 windows that can be opened. In the absence of a ventilation system in a comparable room, the effectiveness of a room air cleaner was also investigated.
Competing Interest Statement
The company Trotec GmbH (Heinsberg, Germany) financially supported the investigations. The room air cleaner of the type TAC V+ was provided by Trotec on loan free of charge for the investigations. This support has no effect on the investigations or results.
Funding Statement
The company Trotec GmbH (Heinsberg, Germany) financially supported the investigations. The room air cleaner of the type TAC V+ was provided by Trotec on loan free of charge for the investigations. This support has no effect on the investigations or results. No other/further funding from third parties.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable. No humans or animals involved in the investigations.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data can be provided upon request.
